22 Steps
Maximum: 8 CME cr., 8 MOC pts.
0 new discussion posts (1 published)
Sign in to view your progression
Program Overview
Learning Objectives
Target Audience
Credit Designation
Disclosure/Disclaimer

Program Overview

This enduring activity is based on recordings of the live activity, The Liver Meeting® 2016 Postgraduate Course, provided November 12, 2016.

COMPONENTS
Online:
-Narrated modules each 20-25 minutes in length 
-Pre-and post-test questions for each module
-Evaluation

Media: Internet
Release date: February 23, 2017
Expiration date: January 31, 2018
Time to complete each module: 30 minutes

System Requirements:
iPad/iPhone: iOS iPad or iPhone devices with iOS 7.0 with the latest LiverLearning® iOS App installed.
Click here to download it : LiverLearning® iOS App
Android devices: Requires Android 4.1 and up with the latest LiverLearning® App installed.
Click here to download it : LiverLearning® Android App
Desktop/Laptop Requirements:
Medium or Combination of Media Used:
- A recent web browser (cookies and javascript enabled) compatible with HTML5 applications
- Flash Player 9+ is required in order to view the modules and complete the accredited course. If you cannot start a module please click here to download and install the current version of the Flash Player.
- Operating system: MacOS/Windows

Internet Connection:
Broadband is recommended but not a must, users in locations with slow internet connection or with a 3G connection may participate in this program.
While it is in the best interest of participants to take the exam through a broadband connection or an LTE (4G) cellular connection rather than through a much slower connection, it is not an absolute requirement.

Screen Resolution:
iOS Apps: this complete program will adapt itself to fit with iPhone or iPad screens
Desktop/Laptop Screens: 800 x 600 or better, 1024 x 768 is preferred

Copyright:
All faculty in this activity have given their permission for publication OR ©2016 AASLD

Contact Information:
For questions on CME/MOC content or the activity web site, contact education@aasld.org.

Upon completion of this activity, participants will be able to:

• Identify the management options available for common liver problems and the benefits and risks of each approach
• Recommend optimal management of patients with common liver problems and engage patients in shared-decision making
- Hepatologists
- Gastroenterologists that care for patients with liver disease

Continuing Medical Education (CME)

The American Association for the Study of Liver Diseases (AASLD) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. AASLD designates this enduring online activity for a maximum of 8.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Maintenance of Certification (MOC)

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 8.0 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 8.0 MOC points in the American Board of Pediatric’s (ABP) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABP MOC credit.

CME Credits

Physicians and other health care professionals seeking AMA PRA Category 1 Credits™ for this enduring medical education activity must complete the pre-test(s), view the presentation(s), successfully pass the post-test(s) for each module with a score of 70% or better, and complete an evaluation.

MOC Points

Physicians seeking ABIM and/or ABP MOC points must complete the CME evaluation in addition to completing the pre-test(s), viewing the presentation(s) and successfully passing the post-test(s) for each module for which they wish to receive points with a score of 70% or better. MOC points will be reported to the ABIM and ABP between the 15th and the 20th of each month, for participants who successfully complete the MOC pre- and post-tests.

Your MOC points will NOT be reported to ABIM and/or ABP until you have indicated to us that you are completely done with all of the lectures for which you wish to receive points. When you are certain that you have completed all of the lectures you wish to complete, please proceed to the “Final Evaluation & Certificate/Completion Confirmation” step.

Complete the Final Evaluation form and download your certificate/Completion Confirmation. Once the certificate has been downloaded the points you have earned will be submitted to ABIM and/or ABP. YOU WILL NOT BE ABLE to earn any additional CME Credits or MOC points for any other lectures related to the Postgraduate Course (You may still review any of the lectures for information purposes only).  

Needs Statement

In 2016, the first group of ABIM certified transplant hepatologists will be due for recertification along with those who will have recently completed a fellowship in transplant hepatology. A comprehensive, focused course is needed to review the material that will be covered on the exam as represented by the ABIM blueprint.

 

Core Competencies

This activity was planned in the context of the following ACGME/IOM/IPEC competencies: Patient care and Procedural Skills, Medical knowledge, Systems-based practice, Practice-based learning and improvement, Patient-centered care, Work in interdisciplinary teams, Evidence-based practice, Quality improvement, Values/Ethics for interprofessional practice, Roles/Responsibilities, Interprofessional communication, and Teams and teamwork. 

Use of Professional Judgment
AASLD ACT Programs and other CME Activities available on LiverLearning® eLearning Portal and LiverLearning mobile eLearning Apps, including all educational links are intended to be used as a tool to assess the hepatology base medical knowledge of the learner. The information presented relates to basic principles of diagnosis and therapy, and is meant in no way to substitute for an individual patient assessment based upon the healthcare provider’s examination of the patient and consideration of laboratory data and other factors unique to the patient.

Drugs and Doses
When prescribing medications, the health professional is advised to check the prescribing information accompanying each drug to verify conditions of use and to identify any changes in drug dosage schedule or contraindications.

AASLD Disclosure Statement
AASLD is an independent, professional organization that does not endorse specific procedures or products of any pharmaceutical/biotech concern. 
This program has been independently planned by AASLD Education Committee.

Faculty, Planner and AASLD Staff Disclosures

This live educational activity has been planned in accordance with AASLD and ACCME Standards of Commercial Support by members of the Postgraduate Course faculty and the following planning committees: AASLD Education Committee, Scientific Program Committee, and the Governing Board.

As an accredited provider, AASLD requires individuals involved in the planning of continuing medical education (CME) activities to disclose all financial relationships, including those of their spouse or partner, with a commercial interest within the past 12 months.  A commercial interest is defined as any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients.  All conflicts of interest are resolved prior to participation.

Statement on off-label and investigational use:  Speakers are asked to make a reasonable effort to identify during their presentation any discussion of off-label or investigative use or application of a product or device.

Financial disclosures will appear after the title slide of each speaker presentation.

Postgraduate Course Faculty Disclosures

Naga P. Chalasani, MD, FAASLD
Consulting: AbbVie, Domain, DS Biopharma, Lilly, NuSirt, Tobira
Grant/Research Support: Galectin, Gilead, Intercept

Henry L. Chan, MD
Advisory Committees or Review Panels: AbbVie, Bristol-Myers Squibb, Gilead, Janssen, Novartis Pharmaceutical, Roche
Speaking and Teaching: Echosens

Marc G. Ghany, MD, FAASLD
Nothing to Disclose

Pere Gines, MD 
Advisory Committees or Review Panels: Ikaria, Noorik, Promethera
Grant/Research Support: Ferring Pharmaceuticals, Grifols, Sequana

Guadalupe Garcia-Tsao, MD, FAASLD
Advisory Committees or Review Panels: AbbVie, Conatus, Exalenz, Fibrogen, Intercept, LAT Pharma
Consulting: Galectin

Robert J. Fontana, MD, FAASLD
Consulting: CLDF
Grant/Research Support: Bristol-Myers Squibb, Gilead, Janssen

Kris V. Kowdley, MD, FAASLD 
Advisory Committees or Review Panels: AbbVie, Enanta, Gilead, Intercept, Merck, Novartis, Trio Health, Verylx
Grant/Research Support: AbbVie, Evidera, Galectin, Gilead, Immuron, Intercept, Merck, NGM Biopharma, Novartis, Tobira, Trio Health
Speaking and Teaching: Gilead, Intercept

Laura M. Kulik, MD
Consulting: Blueprint, Gilead

Josep M. Llovet, MD, FAASLD 
Consulting: Bayer Pharmaceuticals, Biocompatibles, Blueprint Medicines, Boehringer-Ingelheim, Bristol-Myer Squibb, Celsion, Eli Lilly Pharmaceuticals, GlaxoSmithKline, Novartis
Grant/Research Support: Bayer Pharmaceuticals, Boehringer-Ingelheim, Bristol-Myers Squibb

Anna S. Lok, MD, FAASLD 
Grant/Research Support: Bristol-Myers Squibb, Gilead

Cara L. Mack, MD 
Nothing to Disclose

Timothy R. Morgan, MD, FAASLD 
Grant/Research Support: AbbVie, Bristol-Myers Squibb, Genentech, Gilead, Merck

Karen F. Murray, MD 
Grant/Research Support: Gilead
Stock Shareholder: Merck

Mindie H. Nguyen, MD, FAASLD
Advisory Committees or Review Panels: Bristol-Myers Squibb, Gilead
Consulting: Gilead Sciences, Inc.
Grant/Research Support: Bristol-Myers Squibb, Gilead Sciences, Inc.

Victor J. Navarro, MD, FAASLD 
Nothing to Disclose

Patrick G. Northup, MD, MHES 
Nothing to Disclose

Marion G. Peters, MD, FAASLD 
Advisory Committees or Review Panels: Abbott, Gilead, J&J, Roche
Consulting: Merck
Employment: Hoffman La Roche -Spouse

Mary E. Rinella, MD, FAASLD 
Advisory Committees or Review Panels: AbbVie, Intercept
Consulting: Fibrogen, NGM, Shire

Lewis R. Roberts, PhD, FAASLD
Grant/Research Support: ARIAD Pharmaceuticals, Bristol-Myers Squibb, BTG, Five Prime Therapeutics, Gilead Sciences, Inova Diagnostics, Wako Diagnostics

Eugene R. Schiff, MD, FAASLD
Advisory Committees or Review Panels: Arrowhead, Astrazeneca, Bristol-Myers Squibb, CVS, Gilead, Janssen, Merck, Pfizer, Salix Pharmaceutical
Consulting: Acorda
Grant/Research Support: AbbVie, Beckman, Beckman Coulter, Bristol-Myers Squibb, Conatus, Discovery Life Sciences, Gilead, Intercept, Janssen, Medmira, Merck, Orasure Technologies, Ortho JNH, Roche Molecular, Siemens

Amit G. Singal, MD, MS
Advisory Committees or Review Panels: Bayer, Wako DIagnostics
Grant/Research Support: Gilead
Speaking and Teaching: Bayer

Ronald J. Sokol, MD, FAASLD
Advisory Committees or Review Panels: Yasoo Health, Inc.
Consulting: Alexion, Alnylam, Ikaria, Otsuka American Pharmaceuticals, Retrophin, Roche
Grant/Research Support: FFF Enterprises, Mead Johnson Nutritionals, Shire/Lumena

Elizabeth K. Speliotes, MD, PhD, MPH 
Nothing to Disclose

Norah Terrault, MD, MPH
Advisory Committees or Review Panels: Biotest, Eisai
Consulting: Achillion, Bristol-Myers Squibb, CoCrystal, Merck
Grant/Research Support: AbbVie, Biotest, Eisai, Gilead, Merck, Novartis, Vertex

Heiner Wedemeyer, MD
Advisory Committees or Review Panels: Abbott, AbbVie, Bristol-Myers Squibb, Eiger, Falk, Gilead, GlaxoSmithKline, MSD, Novartis, Roche, Roche Diagnostics, Transgene
Consulting: MyrGmbH
Grant/Research Support: Abbott, Gilead, MSD, Novartis, Roche, Roche Diagnostics
Speaking and Teaching: AbbVie, Bristol-Myers Squibb, Gilead, ITF, MSD, Novartis


The Liver Meeting Planner Disclosures 


Gavin E. Arteel, PhD, FAASLD (Scientific Program Committee)
Nothing to Disclose

Jasmohan Bajaj, MD, FAASLD (Education Committee)
Consulting: Abbott, Intercept, Norgine, and Valeant 
Grant/Research Support: Grifols ,Salix,
 
Jorge A. Bezerra, MD, FAASLD (Governing Board)
Grant/Research Support: CHMC, Gilead, Molecular Genetics Laboratory 


Carla W. Brady, MD, MHS (Scientific Program Committee)
Nothing to Disclose

Kimberly A. Brown, MD, FAASLD (Scientific Program Committee and Governing Board)
Advisory Committees or Review Panels: AbbVie, Bristol Myers Squibb, CLDF, Gilead Janssen, Merck
Grant/Research Support: AbbVie, Duke Medical Research, Gilead, Janssen, Merck
Speaking and Teaching: CLDF

Kyle E. Brown, MD, FAASLD (Education Committee)
Nothing to Disclose

Elizabeth M. Brunt, MD, FAASLD (Education Committee)
Consulting: AXS Consulting, Olson Research Group

Kenneth D. Chavin, MD, PhD (Scientific Program Committee)
Grant/Research Support: Bridge to Life, Gilead, Novartis, Sanofi

Yogesh K. Chawla, MD, DM (Education Committee)
Nothing to Disclose

Amanda J. Chaney, MSN, ARNP, FNP-BC (Education Committee)
Nothing to Disclose

Mark J. Czaja, MD, FAASLD (Governing Board)
Advisory Committees/Review Panels: Verlyx Pharma Inc. 
Grant/Research Support: Verlyx Pharma Inc.

Robert J. Firpi, MD (Education Committee)
Nothing to Disclose

Michael W. Fried, MD, FAASLD (Education Committee and Governing Board)
Consulting: AbbVie, Bristol-Myers Squibb, Gilead, Janssen, Merck
Grant/Research Support: AbbVie, Bristol-Myers Squibb, Gilead, Janssen, Merck
Stock Shareholder: Target PharmaSolutions

HoChong Gilles, FNP (Education Committee)
Nothing to Disclose

Stephen A. Harrison, MD (Education Committee)
Advisory Committees or Review Panels: CLDF, Fibrogen, Intercept, Merck, Nimbus Discovery, Pfizer Zafgen
Consulting: HGM Biopharmaceuticals, Medivation
Grant/Research Support: Genfit
Speaking and Teaching: AbbVie, CLDF, Gilead, Merck 

Julie Heimbach, MD (Governing Board)
Nothing to Disclose

Wikrom Karnsakul, MD (Education Committee)
Nothing to Disclose

Saul J. Karpen, MD, PhD (Scientific Program Committee)
Nothing to Disclose

Andrew P. Keaveny, MD (Education and Scientific Program Committee)
Nothing to Disclose

W. Ray Kim, MD, MBA (Governing Board)
Advisory Committees/Review Panels: Gilead, Intercept, Merck

Cynthia Levy, MD (Scientific Program Committee)
Advisory Committee or Review Panel: Target Pharmasolutions
Board Membership: Liver Transplantation
Consulting: Intercept, Novartis
Grant/Research Support: CymaBay, Gilead, Intercept Novartis, NGM, Shire, Tobira
Speaking and Teaching: Medscape

Keith D. Lindor, MD, FAASLD (Scientific Program Committee and Governing Board)
Advisory Committees/Review Panels: Intercept, Shire

Anna S. Lok, MD, FAASLD (Scientific Program Committee and Governing Board)
Grant/Research Support: Bristol-Myers Squibb, Gilead

Richard Manch, MD, FAASLD (Education Committee)
Speaking and Teaching:  AbbBie, Bayer, Bristol Myers Squibb, Gilead, Intercept, Merck, Salix

David C. Mulligan, MD, FACS (Education Committee)
Nothing to Disclose

Mindie Nguyen, MD, MAS, FAASLD (Education Committee)
Advisory Committees or Review Panels: Bristol-Myers Squibb, Gilead
Consulting: Gilead Sciences, Inc. 
Grant/Research Support: Bristol-Myers Squibb, Gilead Sciences, Inc.

K. Rajender Reddy, MD, FAASLD (Governing Board)
Advisory Committees or Review Panels: AbbVie, Bristol Myers Squibb, Gilead, Janssen, Merck
Grant/Research Support: AbbVie, Bristol Myers Squibb, Gilead, Janssen, Merck

Ronald J. Sokol, MD, FAASLD (Scientific Program Committee and Governing Board)
Advisory Committees or Review Panels: Yasoo Health, Inc.
Consulting: Alexion, Alnylam, Ikaria, Otsuka American Pharmaceuticals, Retrophin, Roche
Grant/Research Support: FFF Enterprises, Mead Johnson Nutritionals, Shire/Lumena

Grace L. Su, MD, FAASLD (Education Committee)
Nothing to Disclose
 
Ayako Suzuki, MD, PhD, MSc (Education Committee)
Consulting: Novartis

Gyongi Szabo, MD, PhD, FAASLD (Governing Board)
Advisory Committees or Review Panels: Alcohol Research and Health (NIAAA), Bile Acid Council, Cytatx, GALAXY Project, Glympse Bio, Janssen Research & Development, Nature Reviews in Gastro & Hepatology, NIH ExRNA Program, Prevent Cancer Foundation, Trek Therapeutics, University of Colorado Alcohol Center, University of Pittsburgh, MSTP EAB, University of Southern California Liver Center, Yale University Liver Center
Board Membership: ACER, Heptalogy
Consulting: Novartis, Orbimed, Roviant, Salix, Tobira, Verlyx
Grant/Research Support: NIH-NIAAA, Bristol-Myers Squibb, Gilead, Genfit, Genentech, University of Florida, Intercept, Takeda, Tobira, Vertex

Lisa B. VanWagner, MD (Education Committee)
Nothing to Disclose

Maria Luisa Yataco, MD (Education Committee)
Nothing to Disclose

Atif Zaman, MD, MPH (Education Committee)
Advisory Committees or Review Panels: Bristol-Myers Squibb
Grant/Research Support: Gilead Sciences, Merck

Maintenance of Certification Task Force Disclosures

Oren K. Fix, MD, MSc, FAASLD
Nothing to disclose

Andrew P. Keaveny, MD
Other (Expert Testimony): UpToDate Inc

Ayman A. Koteish, MD, FAASLD
Nothing to disclose

K. Gautham Reddy, MD      
Grants/Research Support:  Merck; Ocera, Intercept, Genfit, Mallinckrodt 
Advisory Committee or Review Panels: Gilead, Intercept 
Speaking and Teaching: Intercept 
Leadership in Related Society: Board, Committee, Journal:  AASLD Training and Workforce Committee Member, AASLD MOC Taskforce, ACG Training Committee Member

Mark W. Russo, MD, FAASLD
Grants/Research Support:  Merck, Salix
Speaking and Teaching: Intercept, Gilead, AbbVie, Salix

Richard K. Sterling, MD, FAASLD
Grants/Research Support: Merck, Roche/Genetech, Gilead, Bayer, BMS, AbbVie
Advisory Committee or Review Panels: Merck, Salix, Bayer, BMS, AbbVie, Gilead, Baxter, Viiv, Pfizer

AASLD Staff Disclosures

Julie Deal
Nothing to Disclose

Katie Duggan
Nothing to Disclose  

Steven  Echard, IOM, CAE, CEO
Nothing to Disclose

Stephanie Graham
Nothing to Disclose

Janeil Klett
Nothing to Disclose

Jessica Jessop
Nothing to Disclose

Johonna Nuby
Nothing to Disclose

Melissa Parrish-Boagey
Nothing to Disclose

Allyson Petty
Nothing to Disclose

Denise Seise
Nothing to Disclose

Anne Wrobel
Nothing to Disclose

Pre-activity questionnaire
Please login here or create an account to view this content.
Postgraduate Course: Introduction
Hepatitis B Immune Tolerant Phase
MOC & CME
A Patient with Early Stage Hepatitis C
MOC & CME
Chronic Hepatitis C: The View from the Pediatric Clinic
Hepatitis E in Immunosuppressed Patient
MOC & CME
Application of Pharmacogenomics to Clinical Practice
MOC & CME
Use of Anti-coagulants in Chronic Liver Disease
MOC & CME
Herbal and Health Supplements in Patients With Chronic Liver Disease
MOC & CME
Pregnancy and Autoimmune Hepatitis
MOC & CME
Alcoholic Hepatitis
MOC & CME
Evaluating Obese Persons With Abnormal Liver Chemistries
MOC & CME
Hepatocellular Carcinoma Surveillance
MOC & CME
Evaluation of the Incidental Solitary Liver Lesion
MOC & CME
Impaired Renal Function in Endstage Liver Disease
MOC & CME
Role of Beta-blockers in Decompensated Liver Disease
MOC & CME
Precision Medicine for Liver Disease
Genetic Testing in Pediatric Liver Diseases
MOC & CME
Adults With Inherited Liver Diseases
MOC & CME
Personalized Management of HCC
MOC & CME
Pearls From the Master Clinician
Final Evaluation & Certificate/Completion Confirmation